Cargando…
A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer
BACKGROUND: Medical image analysis has evolved to facilitate the development of methods for high-throughput extraction of quantitative features that can potentially contribute to the diagnostic and treatment paradigm of cancer. There is a need for further improvement in the accuracy of predictive ma...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789647/ https://www.ncbi.nlm.nih.gov/pubmed/36564734 http://dx.doi.org/10.1186/s12880-022-00956-6 |
_version_ | 1784859000122114048 |
---|---|
author | McAnena, Peter Moloney, Brian M. Browne, Robert O’Halloran, Niamh Walsh, Leon Walsh, Sinead Sheppard, Declan Sweeney, Karl J. Kerin, Michael J. Lowery, Aoife J. |
author_facet | McAnena, Peter Moloney, Brian M. Browne, Robert O’Halloran, Niamh Walsh, Leon Walsh, Sinead Sheppard, Declan Sweeney, Karl J. Kerin, Michael J. Lowery, Aoife J. |
author_sort | McAnena, Peter |
collection | PubMed |
description | BACKGROUND: Medical image analysis has evolved to facilitate the development of methods for high-throughput extraction of quantitative features that can potentially contribute to the diagnostic and treatment paradigm of cancer. There is a need for further improvement in the accuracy of predictive markers of response to neo-adjuvant chemotherapy (NAC). The aim of this study was to develop a radiomic classifier to enhance current approaches to predicting the response to NAC breast cancer. METHODS: Data on patients treated for breast cancer with NAC prior to surgery who had a pre-NAC dynamic contrast enhanced breast MRI were included. Response to NAC was assessed using the Miller–Payne system on the excised tumor. Tumor segmentation was carried out manually under the supervision of a consultant breast radiologist. Features were selected using least absolute shrinkage selection operator regression. A support vector machine learning model was used to classify response to NAC. RESULTS: 74 patients were included. Patients were classified as having a poor response to NAC (reduction in cellularity < 90%, n = 44) and an excellent response (> 90% reduction in cellularity, n = 30). 4 radiomics features (discretized kurtosis, NGDLM contrast, GLZLM_SZE and GLZLM_ZP) were identified as pertinent predictors of response to NAC. A SVM model using these features stratified patients into poor and excellent response groups producing an AUC of 0.75. Addition of estrogen receptor status improved the accuracy of the model with an AUC of 0.811. CONCLUSION: This study identified a radiomic classifier incorporating 4 radiomics features to augment subtype based classification of response to NAC in breast cancer. |
format | Online Article Text |
id | pubmed-9789647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97896472022-12-25 A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer McAnena, Peter Moloney, Brian M. Browne, Robert O’Halloran, Niamh Walsh, Leon Walsh, Sinead Sheppard, Declan Sweeney, Karl J. Kerin, Michael J. Lowery, Aoife J. BMC Med Imaging Research BACKGROUND: Medical image analysis has evolved to facilitate the development of methods for high-throughput extraction of quantitative features that can potentially contribute to the diagnostic and treatment paradigm of cancer. There is a need for further improvement in the accuracy of predictive markers of response to neo-adjuvant chemotherapy (NAC). The aim of this study was to develop a radiomic classifier to enhance current approaches to predicting the response to NAC breast cancer. METHODS: Data on patients treated for breast cancer with NAC prior to surgery who had a pre-NAC dynamic contrast enhanced breast MRI were included. Response to NAC was assessed using the Miller–Payne system on the excised tumor. Tumor segmentation was carried out manually under the supervision of a consultant breast radiologist. Features were selected using least absolute shrinkage selection operator regression. A support vector machine learning model was used to classify response to NAC. RESULTS: 74 patients were included. Patients were classified as having a poor response to NAC (reduction in cellularity < 90%, n = 44) and an excellent response (> 90% reduction in cellularity, n = 30). 4 radiomics features (discretized kurtosis, NGDLM contrast, GLZLM_SZE and GLZLM_ZP) were identified as pertinent predictors of response to NAC. A SVM model using these features stratified patients into poor and excellent response groups producing an AUC of 0.75. Addition of estrogen receptor status improved the accuracy of the model with an AUC of 0.811. CONCLUSION: This study identified a radiomic classifier incorporating 4 radiomics features to augment subtype based classification of response to NAC in breast cancer. BioMed Central 2022-12-23 /pmc/articles/PMC9789647/ /pubmed/36564734 http://dx.doi.org/10.1186/s12880-022-00956-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research McAnena, Peter Moloney, Brian M. Browne, Robert O’Halloran, Niamh Walsh, Leon Walsh, Sinead Sheppard, Declan Sweeney, Karl J. Kerin, Michael J. Lowery, Aoife J. A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer |
title | A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer |
title_full | A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer |
title_fullStr | A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer |
title_full_unstemmed | A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer |
title_short | A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer |
title_sort | radiomic model to classify response to neoadjuvant chemotherapy in breast cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789647/ https://www.ncbi.nlm.nih.gov/pubmed/36564734 http://dx.doi.org/10.1186/s12880-022-00956-6 |
work_keys_str_mv | AT mcanenapeter aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT moloneybrianm aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT brownerobert aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT ohalloranniamh aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT walshleon aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT walshsinead aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT shepparddeclan aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT sweeneykarlj aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT kerinmichaelj aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT loweryaoifej aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT mcanenapeter radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT moloneybrianm radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT brownerobert radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT ohalloranniamh radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT walshleon radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT walshsinead radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT shepparddeclan radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT sweeneykarlj radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT kerinmichaelj radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer AT loweryaoifej radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer |